Bioethics Blogs

Hype, Money and Stem Cells

Michael Hiltzik of the Los Angeles Times used newly published research by Kalina Kamenova and Timothy Caulfield [abstract] to write a scathing article largely focused on the California Institute for Regenerative Medicine (CIRM):

New study: Stem cell field is infected with hype

This conclusion is scarcely novel, but both the academic analysis and the polemical journalistic commentary are welcome. The researchers examined “the portrayal of translational stem cell research in major daily newspapers in Canada, the United States, and the United Kingdom between 2010 and 2013” and found that optimistic perspectives outnumbered pessimistic ones by more than five to one, with less than a third of the reports being neutral.

Kamenova and Caulfield conclude by essentially pinning the responsibility on scientists for “authoritative statements … regarding unrealistic timelines.” Hiltzik, on the other hand, “wouldn’t give journalists this much of a pass,” noting their complicity in exaggerating promises of breakthroughs and cures.

In fact, there is plenty of criticism to spread around.

There are also long-term effects of stem-cell hype. Many people are still predisposed to believe hucksters — and why wouldn’t they be? Weren’t we promised cures a decade ago?

Blog comments reveal that some people now think that the pharmaceutical multinationals are in cahoots with the FDA to prevent treatments from becoming available. (The discussion at this post, in which Paul Knoepfler explains the need for regulation, is one of the better threads.) It is therefore hardly surprising that desperate patients are willing to travel to Mexico, or the Philippines, or the Bahamas, or elsewhere, and to spend thousands of dollars on what are almost certainly placebos at best.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.